We are live on ! Find out more
MGX icon

Metagenomi Therapeutics
MGX

50 hedge funds and large institutions have $140M invested in Metagenomi Therapeutics in 2024 Q1 according to their latest regulatory filings, with 50 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

35.53% more ownership

Funds ownership: 0% → 35.53% (+36%)

Holders
50
Holders Change
+50
Holders Change %
–
% of All Funds
0.72%
Holding in Top 10
2
Holding in Top 10 Change
+2
Holding in Top 10 Change %
% of All Funds
0.03%
New
50
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
RCM
RA Capital Management
Massachusetts
+$20.1M
2
NHAS
Novo Holdings A/S
Denmark
+$20M
3
FCM
Farallon Capital Management
California
+$15.4M
4
PHS
PFM Health Sciences
California
+$14.6M
5
HA
HHLR Advisors
Cayman Islands
+$8.94M

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
RCM
1
RA Capital Management
Massachusetts
$18.4M +$20.1M +1,744,415 New
NHAS
2
Novo Holdings A/S
Denmark
$18.3M +$20M +1,739,175 New
FCM
3
Farallon Capital Management
California
$14.2M +$15.4M +1,343,201 New
PHS
4
PFM Health Sciences
California
$13.4M +$14.6M +1,267,002 New
HA
5
HHLR Advisors
Cayman Islands
$8.21M +$8.94M +777,768 New
Millennium Management
6
Millennium Management
New York
$7.57M +$8.59M +747,548 New
Citadel Advisors
7
Citadel Advisors
Florida
$7.52M +$8.32M +723,901 New
EAM
8
Eventide Asset Management
Massachusetts
$6.15M +$6.7M +583,041 New
SVGI
9
Sozo Ventures GP II
California
$6.14M +$6.69M +581,577 New
DTC
10
Deep Track Capital
Connecticut
$4.92M +$5.36M +466,232 New
PVI
11
Pura Vida Investments
New York
$4.87M +$5.3M +461,283 New
Point72 Asset Management
12
Point72 Asset Management
Connecticut
$3.92M +$4.27M +371,100 New
Principal Financial Group
13
Principal Financial Group
Iowa
$3.7M +$4.03M +350,859 New
AG
14
Artal Group
Luxembourg
$3.17M +$3.45M +300,000 New
FLSM
15
Frazier Life Sciences Management
California
$2.94M +$3.21M +279,025 New
ECM
16
ExodusPoint Capital Management
New York
$2.4M +$2.62M +227,556 New
Marshall Wace
17
Marshall Wace
United Kingdom
$1.93M +$2.1M +183,027 New
Vanguard Group
18
Vanguard Group
Pennsylvania
$1.89M +$2.06M +179,547 New
ACP
19
Altitude Crest Partners
Connecticut
$1.41M +$1.53M +133,333 New
GCM
20
Ghisallo Capital Management
Massachusetts
$1.32M +$1.44M +125,000 New
BlackRock
21
BlackRock
New York
$1.21M +$1.31M +114,324 New
Norges Bank
22
Norges Bank
Norway
$1.14M +$1.24M +107,892 New
Geode Capital Management
23
Geode Capital Management
Massachusetts
$915K +$997K +86,763 New
Hudson Bay Capital Management
24
Hudson Bay Capital Management
Connecticut
$703K +$766K +66,666 New
LP
25
LMR Partners
United Kingdom
$549K +$598K +52,058 New
1
2

MGX Hedge Fund Activity: Q1 2024 in Review

50 of the 6,943 institutional investors tracked by Wall St. Rank reported a position in Metagenomi Therapeutics (MGX) for Q1 2024, worth a combined $140M.

Buyers outnumbered sellers: 50 funds opened new MGX positions and 0 closed out — a net gain of 50 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was RA Capital Management, opening a new position worth an estimated $20.1M.

  • 50 institutional investors held Metagenomi Therapeutics (MGX) as of Q1 2024, up from 0 in Q4 2023.
  • Funds reported $140M of Metagenomi Therapeutics stock for Q1 2024.
  • 50 funds opened new Metagenomi Therapeutics positions in Q1 2024 and 0 closed out, a net change of +50 holders.
  • The largest Metagenomi Therapeutics buyer in Q1 2024 was RA Capital Management, an estimated $20.1M added.

Based on aggregated 13F filings for Q1 2024.